Loading…
← CockpitCompetitor Analysis › 688197.SS Shouyao Holdings Beijing Co. Ltd. Class AOpen in the cockpit ↗

Shouyao Holdings Beijing Co. Ltd. Class A688197.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology
Momentum neutral 56
Mkt cap
$653M
US dollars, full cap
Free float
56%
of shares outstanding
$/day
$9.41M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-83.2 pp
WACC 9.8%
Hurdle
n/a
no reverse DCF
Next earnings
166 days
3 May 2027
Close · CNYCN¥31.05
1D-1.0%
1W-9.5%
1M-4.1%
3M-16.1%
6M-25.6%
YTD-10.6%
1Y-22.1%
ATR %6.3%
52w lowhigh32.9% off high

What Shouyao Holdings Beijing does

Employees: 172

Shouyao Holdings Beijing at a glance

Size Shouyao Holdings Beijing (688197.SS) is a China Health Care company (Biotechnology) with a market value of $653M, the 3054th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥31.05 on 18 Nov 2026.

Performance Over six months the shares fell 25.6%, against -14.7% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 18 in its peer set.

Growth Revenue grew 4,563.9% over the last twelve months (peer median +18.1%); the operating margin is -92.0% (peer median -78.3%).

Valuation It trades at 38.1× enterprise value to sales against a peer median of 6.9× (4th most expensive of 16).

Capital Return on invested capital runs 83.2 points below its cost of capital (9.8% WACC).

Next results Next results expected around 3 May 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 86688197.SS 75
Six months, rebased to 100: Shouyao Holdings Beijing against the median of its 20 peers (local-currency closes).

Shouyao Holdings Beijing financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥99.9MCN¥8.67MCN¥3.94MCN¥5.23MCN¥1.83M
Revenue growth—+120%-25%+186%—
Gross profitn/aCN¥620,372-CN¥3.29M-CN¥2.45M-CN¥4.95M
EBITDAn/a-CN¥200M-CN¥225M-CN¥211M-CN¥212M
Net income-CN¥18.6M-CN¥129M-CN¥212M-CN¥186M-CN¥174M
Free cash flow-CN¥119M-CN¥140M-CN¥190M-CN¥183M-CN¥150M
Capital expenditureCN¥38.3MCN¥3.20MCN¥8.57MCN¥3.83MCN¥20.7M
Total debtCN¥7.36MCN¥13.6MCN¥6.48MCN¥3.04MCN¥8.09M

Quarterly statements and history in the cockpit →

Shouyao Holdings Beijing competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%0%+50%68822199667729GERN002880KURAJANX301520PRMESRZNATTO688197.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shouyao Holdings Beijing is the large dot.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%0×50×100×6882219966GERNPRMESRZN6886399637688197.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shouyao Holdings Beijing is the large dot.

Shouyao Holdings Beijing competitors and peer comparison

How Shouyao Holdings Beijing compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shouyao Holdings Beijing against its 20 peers (data as of 18 Nov 2026)
Measure688197.SSPeer medianRank in peer set
1-month return-4.1%-7.3%8th highest of 21
6-month return-25.6%-14.7%7th lowest of 18
Distance from 52-week high-32.9%-46.1%4th highest of 21
Revenue growth (TTM)+4,563.9%+18.1%highest of 16
Operating margin-92.0%-78.3%9th highest of 17
EV / Sales38.1×6.9×4th most expensive of 16
ROIC minus cost of capital-83.2 pp-14.9 pp3rd lowest of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%2.6×-8.9%-1.3%
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%48.5×n/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%1.9×n/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%26.8×n/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%

Questions

Which companies are Shouyao Holdings Beijing's closest peers?
The cockpit's peer set: Frontier Biotechnologies (688221.SS), Alphamab Oncology (9966.HK), Steminent Biotherapeutics (7729.TWO), Geron (GERN), Shenzhen Weiguang Biological Products (002880.SZ), Kura Oncology (KURA), Janux Therapeutics (JANX), Getein Biotech (603387.SS).
Is Shouyao Holdings Beijing expensive compared with its peers?
On ev / sales it trades at 38.1× against a peer median of 6.9×, 4th most expensive of 16 in its peer set.
How has Shouyao Holdings Beijing stock performed?
Over six months to 18 Nov 2026 the shares returned -25.6% against -14.7% for the median peer; over one year -22.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.